JonesTrading analyst Soumit Roy has maintained their bullish stance on OKUR stock, giving a Buy rating on March 11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soumit Roy’s rating is based on OnKure Therapeutics’ promising developments and strategic plans for their primary asset, OKI-219. The company is gearing up for a significant year in 2025, with plans to validate OKI-219 both as a standalone treatment and in combination with existing therapies for HR+/HER2- breast cancer. This includes the anticipated release of additional data from their Phase 1 PIKture-01 trial in the second half of 2025, which could serve as a pivotal moment for the company’s progress.
Furthermore, OnKure’s strategy to nominate a pan-mutant PI3Kα inhibitor with enhanced efficacy towards specific mutations by the second quarter of 2025 is seen as a move to capture a larger market share. This initiative positions OnKure in direct competition with other notable players in the field, potentially expanding their market reach. The absence of dose-limiting toxicities in ongoing trials also supports a positive outlook, contributing to the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -23.0% and a 17.53% success rate. Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Precision BioSciences, and Oric Pharmaceuticals.
In another report released on March 11, Oppenheimer also maintained a Buy rating on the stock with a $30.00 price target.